CTC
TEVA icon

Central Trust Company’s Teva Pharmaceuticals TEVA Stock Holding History

Central Trust Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22
Closed -$663 – 1676
2026
Q1 		$663 Sell
22
-6
-21% -$193 ﹤0.01% 1464
2025
Q4 		$874 Buy
+28
New +$690 ﹤0.01% 1386
2025
Q3 		– Sell
-644
Closed -$10.8K – 1514
2025
Q2 		$10.8K Hold
644
– – ﹤0.01% 1103
2025
Q1 		$9.9K Hold
644
– – ﹤0.01% 1110
2024
Q4 		$14.2K Buy
+644
New +$11.7K ﹤0.01% 1038
2024
Q3 		– Sell
-100
Closed -$1.63K – 1521
2024
Q2 		$1.63K Buy
+100
New +$1.54K ﹤0.01% 1304
2020
Q1 		– Sell
-1,847
Closed -$18K – 1212
2019
Q4 		$18K Buy
1,847
+1,700
+1,156% +$15.2K ﹤0.01% 851
2019
Q3 		$1K Sell
147
-2,037
-93% -$15.6K ﹤0.01% 1139
2019
Q2 		$20K Buy
2,184
+1,547
+243% +$18.7K ﹤0.01% 803
2019
Q1 		$10K Hold
637
– – ﹤0.01% 884
2018
Q4 		$10K Hold
637
– – ﹤0.01% 899
2018
Q3 		$14K Sell
637
-100
-14% -$2.32K ﹤0.01% 917
2018
Q2 		$18K Buy
737
+100
+16% +$2.04K ﹤0.01% 840
2018
Q1 		$11K Hold
637
– – ﹤0.01% 963
2017
Q4 		$12K Sell
637
-1,176
-65% -$17.7K ﹤0.01% 956
2017
Q3 		$32K Sell
1,813
-69
-4% -$1.55K ﹤0.01% 758
2017
Q2 		$63K Sell
1,882
-1,284
-41% -$39.7K ﹤0.01% 643
2017
Q1 		$102K Sell
3,166
-1,800
-36% -$61.4K 0.01% 558
2016
Q4 		$180K Sell
4,966
-2,090
-30% -$83.4K 0.01% 468
2016
Q3 		$324K Sell
7,056
-584
-8% -$30.5K 0.02% 355
2016
Q2 		$383K Sell
7,640
-2,608
-25% -$139K 0.03% 329
2016
Q1 		$549K Buy
10,248
+6,960
+212% +$408K 0.04% 278
2015
Q4 		$216K Buy
3,288
+700
+27% +$43.3K 0.02% 413
2015
Q3 		$146K Hold
2,588
– – 0.01% 462
2015
Q2 		$153K Buy
2,588
+20
+0.8% +$1.23K 0.01% 472
2015
Q1 		$160K Sell
2,568
-140
-5% -$8.14K 0.01% 455
2014
Q4 		$155K Sell
2,708
-75
-3% -$4.18K 0.01% 456
2014
Q3 		$149K Hold
2,783
– – 0.01% 469
2014
Q2 		$146K Hold
2,783
– – 0.01% 479
2014
Q1 		$147K Buy
2,783
+943
+51% +$43.6K 0.01% 469
2013
Q4 		$74K Sell
1,840
-4,274
-70% -$168K 0.01% 575
2013
Q3 		$231K Buy
6,114
+122
+2% +$4.76K 0.02% 395
2013
Q2 		$235K Buy
+5,992
New +$233K 0.02% 367

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Central Trust Company's TEVA Position: Q2 2026 in Review

Central Trust Company sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 22 shares — an estimated $663 sold.

Central Trust Company first reported a position in TEVA in Q2 2013 and held it in 33 quarters. The position peaked at $549K in Q1 2016. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Central Trust Company reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Central Trust Company sold 22 Teva Pharmaceuticals shares in Q2 2026, an estimated $663.
  • Central Trust Company first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Central Trust Company's Teva Pharmaceuticals position peaked at $549K in Q1 2016.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.